Relixib^®

Relixib, which contains the active ingredient Etoricoxib, is a potent anti-inflammatory and analgesic medication designed for the management of various chronic and acute conditions. As a member of the nonsteroidal anti-inflammatory drug (NSAID) family, it specifically targets the COX-2 enzyme, offering pain relief with a reduced risk of gastrointestinal side effects.

Osteoarthritis: relieves pain and inflammation, improving joint function. Rheumatoid arthritis: reduces inflammation, pain and stiffness in this autoimmune disorder. Ankylosing spondylitis: provides relief from pain and stiffness in the spine.

Gout: effective in managing pain and inflammation during acute gout attacks. Postoperative pain: short-term treatment of moderate pain associated with dental surgery.

Relixib specifically inhibits the cyclooxygenase-2 (COX-2) enzyme. This selective inhibition crucially reduces the production of proinflammatory prostaglandins, thereby decreasing inflammation, pain and fever without significantly affecting COX-1, which protects the stomach lining and maintains normal platelet function.

Selective COX-2 inhibition: targets inflammation with precision, minimizing the gastrointestinal risks associated with less selective NSAIDs. Comprehensive pain management: effective across a spectrum of inflammatory conditions, ensuring versatility in clinical use.

Lower incidence of gastroduodenal ulceration compared with certain traditional NSAIDs.

Relixib contains etoricoxib 120 mg and comes in a box of 7, 14 or 70 tablets, following the British Pharmacopoeia standard.

Relixib should be prescribed after evaluating the individual needs of the patient and should be used strictly according to the prescribed guidelines.

Relixib is manufactured according to the strict specifications of the British Pharmacopoeia to ensure consistency and superior quality. Crassula Pharma certifies that all its products are manufactured in accordance with GMP parameters.